Indexed by:
Abstract:
Current therapeutic strategies for Alzheimer's disease (AD) mainly focus on amyloid β oligomer (AβO) formation or clearance. However, most of them have failed to yield good clinical results. There is an urgent need to explore an alternative therapeutic target for AD treatments. Recent studies have indicated that the cellular prion protein (PrPC) is one of the cell-surface receptors of AβO that mediates related neurotoxicity. Besides, as a neuroprotective protein, the dimerization of PrPCseems to be critical for its trophic activity. We presume that modulating PrPCreceptor activity could be another potential approach to abrogate AβO toxicity. In the present work, using an aptamer-induced dimerization (AID) strategy, we enforce PrPCdimerization and modulate its neurotrophic signaling. The AID strategy can attenuate AβO toxic action by (i) interfering with AβO-PrPCinteraction and promoting neuroprotective shedding of PrPC(ii) preventing the AβO-induced mitochondrial dysfunction and the caspase-3-induced apoptosis; and (iii) reducing the secretion of inflammatory cytokines and relieving the neuroinflammation microenvironment. Our findings suggest that the strategy targeting PrPCsignaling may shed light on validating new therapeutic strategies in AD. © 2022 American Chemical Society. All rights reserved.
Keyword:
Reprint 's Address:
Email:
Source :
Journal of the American Chemical Society
ISSN: 0002-7863
Year: 2022
Issue: 21
Volume: 144
Page: 9264-9270
1 5 . 0
JCR@2022
1 4 . 5 0 0
JCR@2023
ESI HC Threshold:74
JCR Journal Grade:1
CAS Journal Grade:1
Cited Count:
WoS CC Cited Count: 0
SCOPUS Cited Count: 18
ESI Highly Cited Papers on the List: 0 Unfold All
WanFang Cited Count:
Chinese Cited Count:
30 Days PV: 1
Affiliated Colleges: